Rocketlane
Security and trust center evidence
Summary
Rocketlane has 2 registry-verified rows in the CertReports index, last verified 17 Sep 2026. The strongest row is CSA STAR: STAR Level 1 self-assessment (CAIQ). This page is independent of the vendor’s own trust centre: dates, sources and caveats come from CertReports captures.
Reviewer brief
As of 17 Sep 2026, Rocketlane is listed in the CSA STAR registry with a STAR Level 1 self-assessment (CAIQ) dated 24 Aug 2023. As of 17 Sep 2026, Rocketlane is listed in the EU-US Data Privacy Framework registry with Active status covering the EU-US Certification, UK Extension Certification, and Swiss-US Certification, issued 16 Apr 2025 and expiring 15 Apr 2027. As of 17 Sep 2026, no public evidence found for a SOC 2 report. As of 17 Sep 2026, no public evidence found for HIPAA or a BAA offering. As of 17 Sep 2026, no public evidence found regarding subprocessors.
- CSA STAR: listed in CSA STAR registry, STAR Level 1 self-assessment (CAIQ), issued 24 Aug 2023 (as of 17 Sep 2026).
- EU-US Data Privacy Framework: listed in DPF registry, Active (EU-US, UK Extension, Swiss-US Certifications), issued 16 Apr 2025, expires 15 Apr 2027 (as of 17 Sep 2026).
- SOC 2, HIPAA/BAA, and subprocessors: no public evidence found (as of 17 Sep 2026).
Facts only, each dated; nothing here is inferred, scored or advised. Brief generated 17 Sep 2026; it is regenerated whenever a row changes.
Among project management vendors
2verified rows
Category median 1, across 28 indexed project management vendors. Rocketlane has more verified rows than 89 percent of them.
customer-collaborationprofessional-services-automationproject-deliverypsa
Compare with similar vendors
Pick your own comparisonCompliance grid
Legal artefacts
No DPA, BAA or subprocessor list has been captured from a public page yet. Registry rows above do not depend on this.
Subprocessors
No subprocessor list captured yet.
Similar vendors with evidence
Related by product tags and the Project management category, ranked by shared tags, description similarity and overlapping evidence. Never by popularity.
